Evaluation of [99mTc][Tc-HYNIC/EDDA]-Tyr as a target for metabolic tumor imaging in B16F10 melanoma tumor.

Q3 Medicine
Hemat Yaghoubi Mogadam, Mostafa Erfani, Mohammad Nikpassand, Masoud Mokhtary
{"title":"Evaluation of [<sup>99m</sup>Tc][Tc-HYNIC/EDDA]-Tyr as a target for metabolic tumor imaging in B16F10 melanoma tumor.","authors":"Hemat Yaghoubi Mogadam,&nbsp;Mostafa Erfani,&nbsp;Mohammad Nikpassand,&nbsp;Masoud Mokhtary","doi":"10.22038/AOJNMB.2021.60334.1420","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Clinical interest in metabolic imaging of cancer has been growing in recent years. The increase in protein metabolism of cancer cells is interesting target for metabolic tumor imaging, for which radiolabeled amino acids can be applied. The aim of this study was to evaluate a newly developed radiolabeled amino acid as an imaging protein metabolism in melanoma tumor.</p><p><strong>Methods: </strong>The radiolabeled tyrosine ([<sup>99m</sup>Tc][Tc-HYNIC/EDDA]-Tyr) was prepared and its biological properties was evaluated in B16F10 melanoma tumor. Moreover organs uptake and tumor accumulation were measured in mouse bearing B16F10 melanoma tumor.</p><p><strong>Results: </strong>Radiolabeled tyrosine was attached in B16F10 melanoma cells and showed the cell binding capacity of 13.82±0.73%. In animal study, the accumulation of radiolabeled tyrosine was observed in B16F10 melanoma tumor (2.15±0.09 %ID/g) after 30 min post injection, so that the uptake ratio of tumor to muscle was about 5.11. Through scintigraphy process the melanoma tumor clearly visualized in mice at 30 min post injection.</p><p><strong>Conclusion: </strong>These data suggest that the novel radiotracer ([<sup>99m</sup>Tc][Tc-HYNIC/EDDA]-Tyr) as an protein metabolism imaging agent, is able to transfer into melanoma cells and show great expectation for the clinical application in the imaging of melanoma tumors.</p>","PeriodicalId":8503,"journal":{"name":"Asia Oceania Journal of Nuclear Medicine and Biology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9205849/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asia Oceania Journal of Nuclear Medicine and Biology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22038/AOJNMB.2021.60334.1420","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1

Abstract

Objectives: Clinical interest in metabolic imaging of cancer has been growing in recent years. The increase in protein metabolism of cancer cells is interesting target for metabolic tumor imaging, for which radiolabeled amino acids can be applied. The aim of this study was to evaluate a newly developed radiolabeled amino acid as an imaging protein metabolism in melanoma tumor.

Methods: The radiolabeled tyrosine ([99mTc][Tc-HYNIC/EDDA]-Tyr) was prepared and its biological properties was evaluated in B16F10 melanoma tumor. Moreover organs uptake and tumor accumulation were measured in mouse bearing B16F10 melanoma tumor.

Results: Radiolabeled tyrosine was attached in B16F10 melanoma cells and showed the cell binding capacity of 13.82±0.73%. In animal study, the accumulation of radiolabeled tyrosine was observed in B16F10 melanoma tumor (2.15±0.09 %ID/g) after 30 min post injection, so that the uptake ratio of tumor to muscle was about 5.11. Through scintigraphy process the melanoma tumor clearly visualized in mice at 30 min post injection.

Conclusion: These data suggest that the novel radiotracer ([99mTc][Tc-HYNIC/EDDA]-Tyr) as an protein metabolism imaging agent, is able to transfer into melanoma cells and show great expectation for the clinical application in the imaging of melanoma tumors.

Abstract Image

Abstract Image

Abstract Image

[99mTc][Tc-HYNIC/EDDA]-Tyr作为B16F10黑色素瘤代谢肿瘤成像靶点的评价
目的:近年来,临床对肿瘤代谢成像的兴趣越来越大。癌细胞蛋白质代谢的增加是代谢肿瘤成像的一个有趣的靶点,放射性标记氨基酸可以应用于代谢肿瘤成像。本研究的目的是评估一种新开发的放射性标记氨基酸在黑色素瘤肿瘤中的成像蛋白代谢。方法:制备放射性标记酪氨酸([99mTc][Tc-HYNIC/EDDA]-Tyr),并对其在B16F10黑色素瘤中的生物学特性进行评价。此外,还测量了B16F10黑色素瘤小鼠的器官摄取和肿瘤积累。结果:放射标记酪氨酸能附着于B16F10黑色素瘤细胞,细胞结合能力为13.82±0.73%。在动物实验中,注射后30 min, B16F10黑色素瘤中放射标记酪氨酸的蓄积(2.15±0.09% ID/g),肿瘤对肌肉的摄取比约为5.11。注射后30分钟,通过显像处理,小鼠黑色素瘤清晰可见。结论:上述数据提示,新型放射性示踪剂([99mTc][Tc-HYNIC/EDDA]-Tyr)作为一种蛋白质代谢显像剂,能够转移到黑色素瘤细胞中,在黑色素瘤肿瘤成像中的临床应用前景广阔。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Asia Oceania Journal of Nuclear Medicine and Biology
Asia Oceania Journal of Nuclear Medicine and Biology Medicine-Radiology, Nuclear Medicine and Imaging
CiteScore
1.80
自引率
0.00%
发文量
28
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信